Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study.
From May 1988 to March 1990, 17 consecutive patients with histologically proven malignant mesothelioma were treated with epirubicin 75 mg/sqm i.v. on day 1 and ifosfamide 1.8 gr/sqm/day i.v. from day 1-5. Treatment was repeated every 3 weeks until progression. Fifty-three chemotherapy cycles were administered to the 17 patients treated (median, 3 cycles/patient). No complete responses, 1 partial response, 8 stable diseases and 8 progressions were noted. Toxocity was acceptable and no treatment-related deaths occurred. Actuarial median survival was 6 months. In this study, a combination of full doses of epirubicin and ifosfamide did not prove to be active in malignant mesothelioma.
Magri
M D
MD
Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
Foladore
S
S
Veronesi
A
A
Serra
C
C
Nicotra
M
M
Tommasi
M
M
Grandi
G
G
Monfardini
S
S
Bianchi
C
C
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged
D015251:Epirubicin; D007069:Ifosfamide